Biodynamics
This article was originally published in The Gray Sheet
Executive Summary
Completes a $6.2 mil. equity funding via the issuance of 560,000 shares of series B preferred stock in exchange for $2 mil. in cash and the retirement of $4.2 mil. in convertible debentures. The Tampa, Florida-based manufacturer of specialty surgical products and provider of tissue processing services says the cash funds will be used for the completion of a new U.S. tissue processing facility. Each share of the series B preferred stock will entitle its holder "to receive 8.5% cumulative cash dividends, payable quarterly, and to convert into common stock at $1.10 per share" the company says. As a result of the financing, Biodynamics" series A convertible preferred shareholders will be able to convert their stock into common stock at $1.25 per share. The firm retains an option to redeem the series B stock after three years for 120% of its issue price
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.